VARICELLA ZOSTER VIRUS RECOMBINANT VACCINE

Information current as at: 1 November 2026

The processes outlined in the MSW are not applicable to this medicine. Please contact pbs@health.gov.au or 1800 020 613 for further information.

Legend:

Completed N In progress

Not applicable N Yet to commence

Submission Details

Brand name:: Shingrix®
Form and strength:: Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:: GLAXOSMITHKLINE AUSTRALIA PTY LTD
Condition/indication: (therapeutic use)
Listing requested:: Please see PSD for more information
Funding program:: Please see PSD for more information
Request authority level:: Please see PSD for more information
PBAC Submission type:: New listing (Early Resolution Pathway)
Comment:: --
Other PBAC consideration:: VARICELLA ZOSTER VIRUS RECOMBINANT VACCINE

Submission received for:: July 2023 PBAC meeting
Opportunity for consumer comment:: Open 29/03/2023 and close 24/05/2023 (see PBS Website)
PBAC meeting:: Held on 05/07/2023
PBAC outcome published:: Recommended (see PBAC Outcomes)
Notice of intent submitted:: 15/08/2023
Lodgement of required documentation:: Not applicable
Agreement to listing arrangements:: Not applicable
Government processes:: Not applicable
Medicine listed on the PBS:: Not applicable

PBAC Recommendation:

Please see the Outcomes from the relevant meeting for more information

Public Summary Document:

Case ID

a786

Page last updated

20 March 2024

v.9.16